SEC Form 4/A · accession 0001193805-15-001084
ANTARES PHARMA, INC. · ATRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owners
DEERFIELD MANAGEMENT CO
10% Owner · Other
Deerfield Mgmt L.P.
10% Owner · Other
DEERFIELD PARTNERS, LP
10% Owner · Other
James E Flynn
10% Owner · Other
Deerfield Special Situations Fund, L.P.
10% Owner · Other
Deerfield International Master Fund, L.P.
10% Owner · Other
Period of report
Jun 24, 2015
Accepted (ET)
Jul 1, 2015 · 5:54 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001016169
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF3,F1,F2 | Jun 26, 2015 | S | 22,405 | $2.2508 | D | 3,545,827 | I | Through Deerfield Special Situations Fund, L.P. |
| Common StockF3,F1,F2 | Jun 26, 2015 | S | 65,870 | $2.2508 | D | 8,807,597 | I | Through Deerfield International Master Fund, L.P. |
| Common StockF3,F1,F2 | Jun 26, 2015 | S | 51,755 | $2.2508 | D | 6,920,255 | I | Through Deerfield Partners, L.P. |
| Common StockF3,F1,F2 | Jun 26, 2015 | S | 33,627 | $2.2378 | D | 3,512,200 | I | Through Deerfield Special Situations Fund, L.P. |
| Common StockF3,F1,F2 | Jun 26, 2015 | S | 101,291 | $2.2378 | D | 8,706,306 | I | Through Deerfield International Master Fund, L.P. |
| Common StockF3,F1,F2 | Jun 26, 2015 | S | 79,586 | $2.2378 | D | 6,840,669 | I | Through Deerfield Partners, L.P. |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P., Deerfield Special Situations Fund, L.P. and Deerfield International Master Fund, L.P. (collectively, the "Funds"). Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt, L.P. and Deerfield Management Company, L.P.
- F2In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
- F3This Amendment No. 1 to the Form 4 filed with the Commission on June 26, 2015 is being filed solely to amend errors in the number of shares previously reported as sold on June 26, 2015 by the Funds.
Remarks
Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to Avalanche Biotechnologies, Inc. filed with the Securities and Exchange Commission on July 30, 2014 by Deerfield Mgmt III, L.P., Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Special Situations Fund, L.P., Deerfield Special Situations International Master Fund, L.P., Deerfield Private Design Fund III, L.P. and James E. Flynn.